AIQ is not just about adopting a new technology. We’re talking about a fundamentally different way of thinking. A shift in what’s possible in clinical research, and a new standard for execution.
By reimagining clinical trials as the initial step in designing a service ecosystem, organizations can accelerate time to delivery and lay the groundwork for successful commercialization.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
Understanding how site augmentation services could be leveraged to overcome challenges is not the responsibility of one entity. The most creative and effective solutions arise from collaboration among all stakeholders — sponsors, CROs, service providers, and research sites.
Four key predictions for the future of clinical trials, examining how these changes will revolutionize the speed, efficiency, and reliability of bringing life-saving treatments to market.
The clinical trial process is complex, long, and always arduous. But the results of the drug development process can be amazing, new, safe, effective, life-changing, and life-enhancing therapies.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
This technological shift not only boosts efficiency and profitability for pharmaceutical companies but also speeds up the delivery of innovative therapies to patients.
By moving beyond subjective and heterogeneous criteria and embracing objective brain function measures, the field of psychiatry can achieve greater precision and efficacy in addressing complex disorders.
Many great ideas fail because of a fundamental misunderstanding or underestimation of the unique barriers entrenched within healthcare. Here are some key considerations that innovators from non-healthcare backgrounds need to be prepared for.
To bring cross-agency clinical leaders together, the FDA should establish a Center of Excellence for Rare Diseases. This would bring together specialized staff and resources from multiple review divisions to leverage their expertise about different bodily systems, trial designs, pharmacology, and other specialized fields.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
The promise of these and other food allergy treatments is immense and research and development, in conjunction with clinical care facilities for food allergy patients, will continue to make more treatment options available for more people in the future.
Corticosteroids are a standard first-line treatment for Duchenne muscular dystrophy, but these drugs have many side effects. FDA approval of Italfarmaco’s Duvyzat is the first nonsteroidal drug to pass the agency’s regulatory bar for treating this rare disease.
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
Despite achieving its Phase 3 study's main goal, the results for Point Biopharma's therapy are short of what Novartis radiopharmaceutical Pluvicto achieved in a similarly designed clinical trial. Nevertheless, the data readout should clear the way for Eli Lilly to complete its $1.4 billion acquisition of Point.
Inato recently raised $20 million in Series A2 funding for its tech platform, which enables access to inclusive clinical trials. The two-way platform brings exposure to community-based providers who often are overlooked by Big Pharma for clinical trial sites by allowing providers to apply for clinical trials in which they're interested.